erlotinib-hcl

Description: Erlotinib HCl (formerly OSI-744, OSI744; trade name: Tarceva), the hydrochloride salt of erlotinib, is an EGFR (epidermal growth factor receptor) inhibitor with antitumor activity. It inhibits EGFR with an IC50 of 2 nM in cell-free assays, and is > 1000-fold more sensitive for inhibiting EGFR over human c-Src or v-Abl. Erlotinib is a quinazoline derivative that has been approved by FDA and other countries for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer.

References: Cancer Res. 1997 Nov 1; 57(21):4838-48; Anticancer Drugs. 2004 Jun; 15(5):503-12.

Related CAS: 183321-74-6 (free base); 248594-19-6 (mesylate);

Chemical Name: N-(3-Ethynylphenyl)-6, 7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride.

SMILES Code: COCCOC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCOC.[H]Cl